French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs
Portfolio Pulse from Vandana Singh
Sanofi SA's Q4 earnings were impacted by generic competition for Aubagio, but gains from Dupixent and the launch of Altuviiio and Beyfortus helped offset losses. Operating income fell 5.2% to €2.6 billion, with revenues up 1.8% to €10.92 billion, missing consensus estimates. The company aims to become a pure-play biopharma entity by 2030, with significant sales from new Pharma launches. Sanofi also acquired assets related to Inhibrx Inc's INBRX-101. The company expects a low single-digit percentage decrease in 2024 adjusted EPS due to higher taxes but anticipates a strong rebound next year.
February 01, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi acquired assets related to Inhibrx Inc's INBRX-101, indicating a strategic move to strengthen its portfolio in alpha-1 antitrypsin deficiency treatments.
The acquisition of INBRX-101 assets from Inhibrx Inc by Sanofi is a strategic move to enhance its product portfolio, particularly in the treatment of alpha-1 antitrypsin deficiency. This could potentially lead to positive developments for Inhibrx, reflecting a positive short-term impact on its stock as the market reacts to the acquisition news.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
NEUTRAL IMPACT
Sanofi's Q4 earnings were affected by generic competition but saw growth from Dupixent, Altuviiio, and Beyfortus. The company missed revenue estimates and anticipates a low single-digit EPS decrease in 2024.
While Sanofi faced challenges from generic competition and missed revenue estimates, the growth from Dupixent and new drug launches, along with strategic acquisitions and a focus on becoming a pure-play biopharma company, suggest a balanced outlook. The anticipated EPS decrease in 2024 is a concern, but the company's long-term strategy may mitigate short-term impacts.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100